✦ LIBER ✦

VALIDATING AN INDUSTRY-SPONSORED MODEL COMPARING THE COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

✍ Scribed by Christopher N. Graham; Josephine Mauskopf; Anthony H. Lawson; Haya Ascher-Svanum; David Bruhn; Peter R. Watson

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMH48 VALIDATING A COST-EFFECTIVENESS AN

✍ C Graham; J Mauskopf; AH Lawson; H Ascher-Svanum; D Bruhn; PR Watson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PMH34 Long-Term Cost-Effectiveness of At

✍ K. Rajagopalan; K. O'Day; K. Meyer; A.A. Pikalov iii; A. Loebel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PMH16: ATYPICAL ANTIPSYCHOTICS IN THE TR

✍ D Meddis; P Williams 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Effectiveness and costs of flupentixol c

✍ Tom Stargardt; Paraskevi Mavrogiorgou; Christian A. Gericke; Georg Juckel 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 302 KB

Meta-analysis of drop-out rates in rando

✍ José Luis R. Martin; Víctor Pérez; Montse Sacristán; Fernando Rodríguez-Artalejo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 French ⚖ 647 KB

Implications for Atypical Antipsychotics

✍ Michael W. Jann 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB